drugset
drugset / Trial / NCT06471218

Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia

NCT06471218 ↗

Phase 2 Completed 44 enrolled Beijing Suncadia Pharmaceuticals Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Evaluation of the efficacy and safety of multiple subcutaneous injections of SHR-1918 in patients with hyperlipidemia in poor control: a multicenter, randomized, double-blind, placebo-controlled phase II clinical trials

Timeline

Start
2024-07-02
Primary completion
2025-05-16
Completion
2025-05-16

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1918 Monoclonal antibody — Subcutaneous

Indications

hyperlipidemia